Bayer Edging Closer to Litigation Resolution -- Market Talk

Dow Jones

03/16

1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 16, 2026 10:28 ET (14:28 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2619461137"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619461137\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619461137?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619461137","market":"fut","top_or_hot":-1,"title":"Bayer Edging Closer to Litigation Resolution -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Edging Closer to Litigation Resolution -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Edging Closer to Litigation Resolution -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-16 22:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619461137","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619461137","pubTimestamp":1773671280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BAYRY":"Bayer A.G."},"translate_title":"拜耳距离诉讼解决方案越来越近——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"1428 GMT - The latest developments in Bayer's litigation saga over its Roundup weedkiller support a potential resolution, analysts at UBS say in a research note. The German agricultural and pharmaceutical group has received preliminary approval for its proposed settlement, which is positive, UBS says. An agreement would remove potential risk for the shares and provide closure on the litigation, the analysts say. Some investors are worried about a motion filed in a Missouri court, but even in a worst-case scenario Bayer's shares can't fall much more from current levels, the analysts say. UBS raises its recommendation on Bayer to buy from neutral, lifting its target price to 52 euros from 48 euros. Shares rise 3.9% to 40.15 euros. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 10:28 ET (14:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}